Landscapes / Companies
AVEO Pharmaceuticals, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 3
Drugs
2
in active trials · 3 in all
Trials
2 active
8 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Phase 3 | Aug 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Aug 2027 · Phase 3 trial completes | ||||
| Also tested for | Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | ||||
| Open drug page | |||||
Unmodified immunoglobulin |
Phase 2/3 | Mar 2030Phase 2/3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Mar 2030 · Phase 2/3 trial completes | ||||
| Also tested for | Cachexia; Cancer, Cachexia and 5 more | ||||
| Open drug page | |||||
About
- No active trial
- Tivozanib
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021